Lymphoma, Non-Hodgkin Clinical Trials
6 recruiting trials for Lymphoma, Non-Hodgkin. Eligibility criteria explained in plain English.
TrialFinderData lists 6 Lymphoma, Non-Hodgkin clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 2 is the largest group at 60% (3 studies); the largest phase groups are Phase 2: 3, Phase 1: 2.
Research is led by OncoNano Medicine, Inc. (1), University of Florida (1), American Society of Clinical Oncology (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is Palbociclib (drug, 2 trials), followed by Sunitinib, Temsirolimus.
Track Lymphoma, Non-Hodgkin trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients...
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or...
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
This study will assess the safety, efficacy, and feasibility of ⍺/β CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute...
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a...
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to...
DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
This study will treat patients with B-NHL who have relapsed, progressed, or were intolerant to systemic therapy progressed following prior therapy. This study will help to...
Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma
The goal of this observational cohort study is to learn how toxin and occupational exposures, germline genetic variation, and immune dysregulation relate to B-cell non-Hodgkin...
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are...
Explore Other Conditions
Frequently Asked Questions
There are currently 6 clinical trials for Lymphoma, Non-Hodgkin, with 6 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Lymphoma, Non-Hodgkin, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Lymphoma, Non-Hodgkin, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.